EC
CRSP icon

EcoR1 Capital’s CRISPR Therapeutics CRSP Stock Holding History

EcoR1 Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.8M Hold
1,389,276
– – 3.68% 6
2026
Q1 		$66.1M Hold
1,389,276
– – 2.8% 9
2025
Q4 		$72.9M Hold
1,389,276
– – 3.31% 6
2025
Q3 		$90M Hold
1,389,276
– – 4.32% 6
2025
Q2 		$67.6M Hold
1,389,276
– – 4% 7
2025
Q1 		$47.3M Hold
1,389,276
– – 2.8% 9
2024
Q4 		$54.7M Hold
1,389,276
– – 2.07% 14
2024
Q3 		$65.3M Hold
1,389,276
– – 2.23% 12
2024
Q2 		$75M Hold
1,389,276
– – 2.3% 14
2024
Q1 		$94.7M Buy
+1,389,276
New +$99.5M 2.4% 15
2022
Q1 		– Sell
-1,077,483
Closed -$81.7M – 89
2021
Q4 		$81.7M Buy
+1,077,483
New +$94.1M 2.6% 11
2020
Q2 		– Sell
-30,510
Closed -$1.29M – 52
2020
Q1 		$1.29M Buy
+30,510
New +$1.58M 0.14% 42
2019
Q3 		– Sell
-1,610,250
Closed -$75.8M – 39
2019
Q2 		$75.8M Sell
1,610,250
-268,027
-14% -$10.7M 7.66% 4
2019
Q1 		$67.1M Buy
1,878,277
+1,669,427
+799% +$57.7M 6.18% 4
2018
Q4 		$5.97M Sell
208,850
-291,150
-58% -$10.1M 0.6% 39
2018
Q3 		$22.2M Buy
+500,000
New +$26.2M 2% 15

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital's CRSP Position: Q2 2026 in Review

EcoR1 Capital held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1,389,276 shares worth $75.8M. The position accounts for 3.68% of the portfolio, ranked #6.

EcoR1 Capital first reported a position in CRSP in Q3 2018 and has held it in 16 quarters since. The position peaked at $94.7M in Q1 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • EcoR1 Capital held 1,389,276 shares of CRISPR Therapeutics worth $75.8M as of Q2 2026.
  • EcoR1 Capital left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 3.68% of EcoR1 Capital's portfolio in Q2 2026, its #6 holding.
  • EcoR1 Capital first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 16 quarters since.
  • EcoR1 Capital's CRISPR Therapeutics position peaked at $94.7M in Q1 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.